A detailed history of Twinbeech Capital LP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 535,079 shares of RXRX stock, worth $3.31 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
535,079
Previous 371,247 44.13%
Holding current value
$3.31 Million
Previous $2.78 Million 26.65%
% of portfolio
0.07%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $969,885 - $1.41 Million
163,832 Added 44.13%
535,079 $3.53 Million
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $424,536 - $580,488
57,760 Added 18.43%
371,247 $2.78 Million
Q1 2024

May 15, 2024

BUY
$9.13 - $15.52 $2.86 Million - $4.87 Million
313,487 New
313,487 $3.13 Million
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.26 $881,611 - $1.62 Million
-174,923 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$6.16 - $18.03 $1.08 Million - $3.15 Million
174,923 New
174,923 $1.25 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.